Q: Treatment and further management and what if positive A: Clinical Picture from the DAMA Summary This is a 15-year-old boy with severe lower respiratory tract infection with a working diagnosis of ?Crimean-Congo Haemorrhagic Fever CCHF, complicated by ARDS, bilateral pleural effusion, severe thrombocytopenia platelets dropped to 14,000, septic shock, and MODS, on noradrenaline and BiPAP, with an IgM Brucella weakly positive result as an incidental/co-existing finding. The family took him out against medical advice DAMA after being counselled on the poor prognosis. Below is the management framework for this picture and what changes if the CCHF or Brucella test returns definitively positive. 1. Immediate/ongoing critical care regardless of final confirmation - ICU isolation with barrier nursing — mandatory whenever CCHF is on the differential, since transmission occurs through blood/body fluid contact, not just droplets. All staff need full PPE gown, gloves, eye protection, mask and safe injection/sharps practice - Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 2202-2208. - Hemodynamic support: continue/titrate noradrenaline for septic shock; reassess fluid balance carefully ARDS + shock is a difficult balance. - Respiratory support: he was already on BiPAP for severe hypoxemia; if work of breathing worsens or PaO2/FiO2 falls further, escalate to invasive mechanical ventilation with lung-protective settings low tidal volume, appropriate PEEP given ARDS + bilateral effusions. - Blood product support for coagulopathy/thrombocytopenia: platelet transfusions RDP/SDP as already being given, fresh frozen plasma, and packed red cells as needed. Avoid all unnecessary invasive procedures and intramuscular injections because of high bleeding risk; avoid aspirin/NSAIDs, which impair platelet function. - Broad-spectrum antimicrobial cover for secondary bacterial sepsis meropenem was already appropriate empirically, reassessed against cultures. - Organ support: monitor renal function closely — hemodialysis if AKI develops as part of MODS; monitor liver enzymes, coagulation profile PT/INR, aPTT, and electrolytes daily. - Supportive therapy fluids, electrolyte correction, treating secondary infections, mechanical/renal support remains the backbone of care for viral hemorrhagic fevers because no treatment is definitively proven to alter mortality - CDC Emerging Infectious Diseases review Nasrullah et al., 2024. 2. Specific to suspected CCHF - Ribavirin oral or IV is the only antiviral used clinically, typically for about 10 days, ideally started early in the illness. It was "ordered but not available" at the referring hospital — sourcing ribavirin urgently at the receiving/higher center is a priority - Tintinalli's Emergency Medicine, p. 1127. - Evidence for ribavirin's mortality benefit is genuinely mixed; WHO states there is no specific approved treatment and that, where feasible, ribavirin use should ideally be studied in a trial framework rather than assumed effective. - In a case series from Iran, high-dose methylprednisolone 10 mg/kg x3 days, then 5 mg/kg x2 days added to ribavirin in patients with platelets 50,000 improved platelet/leukocyte recovery and reduced transfusion needs, though it did not clearly reduce mortality — this could be considered given his platelet count of 14,000, but it is not a guideline-mandated step. - Mandatory notification to public health/surveillance authorities in India, via the Integrated Disease Surveillance Programme — CCHF is a notifiable viral hemorrhagic fever, and Gujarat Amreli/Bhavnagar belt, which includes Mahuva has had prior CCHF outbreaks linked to livestock/tick exposure. - Confirmatory testing should go to a reference lab capable of CCHF PCR/serology in India, NIV Pune — a bedside or local screen is not definitive. - Contact tracing: anyone with unprotected exposure to his blood/body fluids family, ambulance staff, hospital staff should be identified for symptom monitoring for up to 14 days; post-exposure ribavirin prophylaxis can be considered for high-risk exposures needlestick, mucosal splash. 3. If the CCHF test comes back POSITIVE - Continue/initiate ribavirin without delay if not already running. - Isolation continues until the patient meets discharge criteria per national protocol typically clinical recovery plus, where available, two negative PCR results — this is not just infection control courtesy, it is required to prevent nosocomial and household transmission. - All body fluids, linen, and waste are handled as biohazard material; if the patient succumbs, safe burial/handling practices apply because the virus remains viable in blood and tissue after death. - Aggressive supportive ICU care as above continues to be the mainstay — blood products, organ support, ventilation. - Realistic counselling: reported case fatality for CCHF ranges from about 3% up to 30-60% in some series, and this patient already has ARDS + septic shock + MODS + severe thrombocytopenia, which independently carry high mortality. The treating team's assessment of "high risk of mortality" communicated to the family is consistent with the severity described. 4. The Brucella IgM "weakly positive" result A weakly positive IgM alone is not diagnostic — it can reflect past exposure, early/evolving infection, or cross-reactivity, and needs confirmation with a standard/Rose Bengal agglutination titer, paired serology, blood culture extended incubation, or PCR before being treated as the primary diagnosis - Goldman-Cecil Medicine, p. 2419-2421. If brucellosis is confirmed which is plausible given rural/animal-exposure demographics that also predispose to CCHF: - Standard regimen: doxycycline 100 mg twice daily plus rifampicin 600-900 mg/day for a minimum of 6 weeks WHO regimen. - For more severe or complicated disease e.g., focal disease, relapse risk: doxycycline plus an aminoglycoside streptomycin or gentamicin for 2-3 weeks, followed by continued doxycycline. - He was already started on doxycycline; adding rifampicin rather than relying on doxycycline alone would align with guideline dosing if Brucella is confirmed as clinically significant. CCHF and brucellosis are not mutually exclusive — both are endemic to the same tick/livestock-exposed rural populations, so a dual picture viral hemorrhagic fever plus incidental or true brucella infection is biologically plausible and both should be worked up in parallel rather than treating one as ruling out the other. 5. Given the family chose to transfer him DAMA - Transport should only proceed with advanced life support continued noradrenaline infusion, oxygen/ventilatory support, cardiac monitoring and ideally accompanied by a doctor/paramedic trained in critical transport. - The receiving center must have ICU + isolation capability for viral hemorrhagic fever and access to ribavirin and blood products platelets especially, given the 14,000 count. - All existing reports blood counts, coagulation profile, cultures, imaging, the Brucella and CCHF serology should travel with the patient to avoid repeating invasive tests in a patient with a bleeding tendency. - The physician's documented warning about the risk of deterioration or death during high-risk transport is medically appropriate and should be reiterated to the family before transfer. Caveat: This response is a synthesis of standard textbook and guideline management for the syndromes described in the discharge note, not an individualized treatment plan — the receiving physicians must tailor management to real-time vitals, labs, and confirmatory test results, since this patient is hemodynamically unstable with multi-organ involvement.
